BriaCell Therapeutics Corp. (BCTX)
NASDAQ: BCTX · Real-Time Price · USD
12.30
+0.45 (3.80%)
Oct 20, 2025, 3:50 PM EDT - Market open
BriaCell Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for BriaCell Therapeutics stock has a target of 40, which predicts a 225.20% increase from the current stock price of 12.3.
Price Target: $40 (+225.20%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 27, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for BriaCell Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 1 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $32 → $40 | Strong Buy | Maintains | $32 → $40 | +225.20% | Aug 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $320 | Strong Buy | Reiterates | $320 | +2,501.63% | Apr 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $150 → $320 | Strong Buy | Maintains | $150 → $320 | +2,501.63% | Feb 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2,250 | Strong Buy | Reiterates | $2,250 | +18,192.68% | Dec 12, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $2,250 | Strong Buy | Reiterates | $2,250 | +18,192.68% | Dec 3, 2024 |
Financial Forecast
Revenue This Year
2.12M
Revenue Next Year
10.20M
from 2.12M
Increased by 380.95%
EPS This Year
-11.56
from -62.19
EPS Next Year
-3.43
from -11.56
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 |
|---|---|---|
| High | 2.2M | 10.6M |
| Avg | 2.1M | 10.2M |
| Low | 2.1M | 9.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 |
|---|---|---|
| High | - | 400.0% |
| Avg | - | 381.0% |
| Low | - | 366.7% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | -12.02 | -3.57 | ||
| Avg | -11.56 | -3.43 | ||
| Low | -11.22 | -3.33 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|
| High | - | - | ||
| Avg | - | - | ||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.